vs

Side-by-side financial comparison of ASGN Inc (ASGN) and CLOVER HEALTH INVESTMENTS, CORP. (CLOV). Click either name above to swap in a different company.

ASGN Inc is the larger business by last-quarter revenue ($970.0M vs $487.7M, roughly 2.0× CLOVER HEALTH INVESTMENTS, CORP.). ASGN Inc runs the higher net margin — 0.6% vs -10.1%, a 10.7% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs -3.0%). ASGN Inc produced more free cash flow last quarter ($9.1M vs $-69.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs -3.2%).

ASGN Inc is a leading U.S.-headquartered professional services and workforce solutions provider. It specializes in supplying skilled talent and consulting services across high-growth segments including information technology, creative, digital, life sciences, and engineering, primarily serving enterprise clients across North America.

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

ASGN vs CLOV — Head-to-Head

Bigger by revenue
ASGN
ASGN
2.0× larger
ASGN
$970.0M
$487.7M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+47.7% gap
CLOV
44.7%
-3.0%
ASGN
Higher net margin
ASGN
ASGN
10.7% more per $
ASGN
0.6%
-10.1%
CLOV
More free cash flow
ASGN
ASGN
$78.1M more FCF
ASGN
$9.1M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
-3.2%
ASGN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ASGN
ASGN
CLOV
CLOV
Revenue
$970.0M
$487.7M
Net Profit
$5.5M
$-49.3M
Gross Margin
27.5%
Operating Margin
2.9%
-10.1%
Net Margin
0.6%
-10.1%
Revenue YoY
-3.0%
44.7%
Net Profit YoY
-73.7%
-123.2%
EPS (diluted)
$0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASGN
ASGN
CLOV
CLOV
Q1 26
$970.0M
Q4 25
$980.1M
$487.7M
Q3 25
$1.0B
$496.6M
Q2 25
$1.0B
$477.6M
Q1 25
$968.3M
$462.3M
Q4 24
$985.0M
$337.0M
Q3 24
$1.0B
$331.0M
Q2 24
$1.0B
$356.3M
Net Profit
ASGN
ASGN
CLOV
CLOV
Q1 26
$5.5M
Q4 25
$25.2M
$-49.3M
Q3 25
$38.1M
$-24.4M
Q2 25
$29.3M
$-10.6M
Q1 25
$20.9M
$-1.3M
Q4 24
$42.4M
$-22.1M
Q3 24
$47.5M
$-9.2M
Q2 24
$47.2M
$7.4M
Gross Margin
ASGN
ASGN
CLOV
CLOV
Q1 26
27.5%
Q4 25
28.9%
Q3 25
29.4%
Q2 25
28.7%
Q1 25
28.4%
Q4 24
29.0%
Q3 24
29.1%
24.5%
Q2 24
29.1%
30.3%
Operating Margin
ASGN
ASGN
CLOV
CLOV
Q1 26
2.9%
Q4 25
5.7%
-10.1%
Q3 25
6.7%
-4.9%
Q2 25
5.8%
-2.2%
Q1 25
4.8%
-0.3%
Q4 24
7.5%
-6.4%
Q3 24
7.7%
-2.7%
Q2 24
7.8%
2.0%
Net Margin
ASGN
ASGN
CLOV
CLOV
Q1 26
0.6%
Q4 25
2.6%
-10.1%
Q3 25
3.8%
-4.9%
Q2 25
2.9%
-2.2%
Q1 25
2.2%
-0.3%
Q4 24
4.3%
-6.6%
Q3 24
4.6%
-2.8%
Q2 24
4.6%
2.1%
EPS (diluted)
ASGN
ASGN
CLOV
CLOV
Q1 26
$0.13
Q4 25
$0.58
Q3 25
$0.87
Q2 25
$0.67
Q1 25
$0.48
Q4 24
$0.94
Q3 24
$1.06
Q2 24
$1.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASGN
ASGN
CLOV
CLOV
Cash + ST InvestmentsLiquidity on hand
$143.6M
$78.3M
Total DebtLower is stronger
$1.5B
Stockholders' EquityBook value
$1.8B
$308.7M
Total Assets
$4.0B
$541.0M
Debt / EquityLower = less leverage
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASGN
ASGN
CLOV
CLOV
Q1 26
$143.6M
Q4 25
$161.2M
$78.3M
Q3 25
Q2 25
Q1 25
Q4 24
$205.2M
$194.5M
Q3 24
$288.0M
Q2 24
$254.8M
Total Debt
ASGN
ASGN
CLOV
CLOV
Q1 26
$1.5B
Q4 25
$1.2B
Q3 25
$1.2B
Q2 25
$1.2B
Q1 25
$1.3B
Q4 24
$1.0B
Q3 24
$1.0B
Q2 24
$1.0B
Stockholders' Equity
ASGN
ASGN
CLOV
CLOV
Q1 26
$1.8B
Q4 25
$1.8B
$308.7M
Q3 25
$1.8B
$340.9M
Q2 25
$1.8B
$344.2M
Q1 25
$1.8B
$336.1M
Q4 24
$1.8B
$341.1M
Q3 24
$1.8B
$342.2M
Q2 24
$1.8B
$324.9M
Total Assets
ASGN
ASGN
CLOV
CLOV
Q1 26
$4.0B
Q4 25
$3.7B
$541.0M
Q3 25
$3.7B
$559.7M
Q2 25
$3.7B
$575.0M
Q1 25
$3.7B
$583.7M
Q4 24
$3.4B
$580.7M
Q3 24
$3.4B
$653.0M
Q2 24
$3.5B
$674.2M
Debt / Equity
ASGN
ASGN
CLOV
CLOV
Q1 26
0.82×
Q4 25
0.65×
Q3 25
0.64×
Q2 25
0.66×
Q1 25
0.72×
Q4 24
0.58×
Q3 24
0.58×
Q2 24
0.57×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASGN
ASGN
CLOV
CLOV
Operating Cash FlowLast quarter
$-66.9M
Free Cash FlowOCF − Capex
$9.1M
$-69.0M
FCF MarginFCF / Revenue
0.9%
-14.1%
Capex IntensityCapex / Revenue
1.0%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$290.6M
$-69.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASGN
ASGN
CLOV
CLOV
Q1 26
Q4 25
$102.3M
$-66.9M
Q3 25
$83.9M
$12.1M
Q2 25
$124.9M
$5.4M
Q1 25
$16.8M
$-16.3M
Q4 24
$100.2M
$34.8M
Q3 24
$135.8M
$50.0M
Q2 24
$90.7M
$44.8M
Free Cash Flow
ASGN
ASGN
CLOV
CLOV
Q1 26
$9.1M
Q4 25
$93.7M
$-69.0M
Q3 25
$72.0M
$11.4M
Q2 25
$115.8M
$4.8M
Q1 25
$6.6M
$-16.5M
Q4 24
$88.9M
$33.3M
Q3 24
$127.9M
$49.6M
Q2 24
$85.4M
$44.4M
FCF Margin
ASGN
ASGN
CLOV
CLOV
Q1 26
0.9%
Q4 25
9.6%
-14.1%
Q3 25
7.1%
2.3%
Q2 25
11.3%
1.0%
Q1 25
0.7%
-3.6%
Q4 24
9.0%
9.9%
Q3 24
12.4%
15.0%
Q2 24
8.3%
12.5%
Capex Intensity
ASGN
ASGN
CLOV
CLOV
Q1 26
1.0%
Q4 25
0.9%
0.4%
Q3 25
1.2%
0.1%
Q2 25
0.9%
0.1%
Q1 25
1.1%
0.0%
Q4 24
1.1%
0.5%
Q3 24
0.8%
0.1%
Q2 24
0.5%
0.1%
Cash Conversion
ASGN
ASGN
CLOV
CLOV
Q1 26
Q4 25
4.06×
Q3 25
2.20×
Q2 25
4.26×
Q1 25
0.80×
Q4 24
2.36×
Q3 24
2.86×
Q2 24
1.92×
6.04×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons